<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T3" position="float">
 <label>Table 3</label>
 <caption>
  <p>Clinical trials employing RNA vaccines in pandemic settings.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Study start</bold>
    </th>
    <th valign="top" align="center" rowspan="1" colspan="1">
     <bold>
      <italic>N</italic>
     </bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine and delivery</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Outcome</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT03014089</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>ZIKA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I/II</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Dec 2016</td>
    <td valign="top" align="center" rowspan="1" colspan="1">90</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>mRNA 1325</bold>, modified nucleotides; LNP-formulated, Antigen: prM-E polyprotein
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Results pending; estimated primary completion date in Sept 2018</td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT03076385</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>INFLUENZA H10N8</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Dec 2015</td>
    <td valign="top" align="center" rowspan="1" colspan="1">201</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>mRNA 1851</bold>, modified nucleotides; LNP-formulated, Antigen: HA of H10N8 A/Jiangxi-Donghu/346/2013
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Interim results published for 100 μg IM (
     <italic>N</italic> = 23) vs. placebo (
     <italic>N</italic> = 8)
     <break/>
     <bold>Safety:</bold> acceptable safety profile
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - HI titers ≥40 in 100% (23/23) of subjects at day 43
     <break/> - MN ≥20 in 87% (20/23) at day 43
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT03345043</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>INFLUENZA H7N9</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">May 2016</td>
    <td valign="top" align="center" rowspan="1" colspan="1">156</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>mRNA 1440</bold>, modified nucleotides; LNP-formulated, Antigen: HA of H7N9 A/Anhui/1/2013
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Results pending; estimated primary completion date in Sept 2018</td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT03325075</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>CHIKUNGUNYA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Aug 2017</td>
    <td valign="top" align="center" rowspan="1" colspan="1">60</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>mRNA 1388</bold>, modified nucleotides; LNP-formulated Antigen: structural polyprotein
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Results pending; estimated primary completion date in Sept 2019</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>This table exclusively lists clinical trials discussed in the text; prM-E, preMembrane-Envelope; HA, Hemagglutinin; HI, hemagglutination inhibition; MN, microneutralization titers; N, number of study participants; IM, intramuscular; ID, intradermal; LNP, lipid nanoparticle</italic>.
  </p>
 </table-wrap-foot>
</table-wrap>
